Pzena Investment Management LLC Acquires 219,541 Shares of Humana Inc. (NYSE:HUM)

Pzena Investment Management LLC increased its position in Humana Inc. (NYSE:HUM - Free Report) by 6.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,828,923 shares of the insurance provider's stock after purchasing an additional 219,541 shares during the quarter. Humana accounts for 3.6% of Pzena Investment Management LLC's portfolio, making the stock its 6th largest position. Pzena Investment Management LLC owned 3.17% of Humana worth $1,013,133,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Riverview Trust Co acquired a new stake in Humana in the first quarter valued at $34,000. Garde Capital Inc. acquired a new stake in shares of Humana in the 1st quarter worth about $36,000. Transce3nd LLC acquired a new stake in shares of Humana in the 4th quarter worth about $38,000. Whipplewood Advisors LLC increased its holdings in shares of Humana by 639.1% in the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after acquiring an additional 147 shares during the period. Finally, Colonial Trust Advisors increased its holdings in shares of Humana by 4,500.0% in the 4th quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock worth $47,000 after acquiring an additional 180 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

HUM stock traded down $3.47 on Friday, reaching $220.08. 4,319,955 shares of the company were exchanged, compared to its average volume of 1,822,171. Humana Inc. has a 12 month low of $207.93 and a 12 month high of $406.46. The stock's fifty day moving average price is $235.46 and its 200 day moving average price is $257.46. The firm has a market capitalization of $26.56 billion, a PE ratio of 15.56, a PEG ratio of 1.55 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. During the same quarter in the previous year, the firm posted $7.23 earnings per share. Humana's revenue was up 8.4% compared to the same quarter last year. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research analyst reports. Barclays set a $268.00 target price on shares of Humana and gave the company an "equal weight" rating in a research note on Thursday, June 12th. Wells Fargo & Company set a $348.00 target price on shares of Humana in a research note on Friday. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Oppenheimer raised their target price on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Finally, Mizuho raised their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $282.57.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.